Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5046 - A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Clinical Research;  Pancreatic Cancer


Koen Lee


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


K. Lee1, R.J. Molenaar2, R. Klaassen2, M.F. Bijlsma3, M.J. Weterman1, D.J. Richel1, M. Wymenga4, H.W.M. van Laarhoven1, J.W. Wilmink5

Author affiliations

  • 1 Medical Oncology, Cancer Center Amsterdam, Academic Medical Center, University of Amsterdam, 1105AZ - Amsterdam/NL
  • 2 Medical Oncology, Cancer Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam/NL
  • 3 Laboratory For Experimental Oncology And Radiobiology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 4 Medical Oncology, Medisch Spectrum Twente (MST), 7500 KA - Enschede/NL
  • 5 Medical Oncology, Academic Medical Center (AMC), Amsterdam/NL


Abstract 5046


Metastasized pancreatic cancer has a dismal survival due to poor responses to chemotherapy. Preclinical research suggests that targeting pancreatic tumor stroma with the Sonic Hedgehog inhibitor LDE225 may improve chemotherapy delivery to the tumor.


We performed a phase IB dose-escalation clinical trial. The primary objectives were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and the anti-tumor efficacy of LDE225 in combination with 1000 mg/m2 gemcitabine and 125 mg/m2 nab-paclitaxel in patients with metastasized pancreatic cancer. The LDE225 dose was to be escalated, gemcitabine and nab-paclitaxel doses were fixed. Treatment evaluation was performed by CT after 2 cycles of therapy according to RECIST 1.1 criteria. Additional diffusion-weighted MRI scans were performed before and after 2 cycles of treatment.


26 patients received study treatment for a median duration of 109 days (IQR 54-245) during a median of 4 (IQR 2-8.5) chemotherapeutic cycles. 6 patients discontinued due to toxicity and 20 patients because of progressive disease. At the starting dose level (400 mg LDE225), 1 out of 6 patients experienced a DLT. Because the DLT and most adverse events occurred in patients who received prior chemotherapeutic treatment we divided the cohort in a chemo-naïve (n = 17) and a prior-chemo group (n = 9). Within the chemo-naive group, the MTD was 800 mg LDE225. In the prior-chemo group, the MTD was 200 mg LDE225. No therapy-related grade 4 adverse events were reported. The most frequent grade 3 reported adverse events were: fatigue (27%), neutropenia (15%) and diarrhea (12%). Of 23 evaluable patients, 6 patients had progressive disease (26%), 8 had stable disease (35%), 8 had a partial response (35%) and 1 patient had a complete response (4%). 12 patients with SD/PR underwent both MRI scans. These patients showed a significant increase in diffusion coefficient after treatment (1.39±0.24 x 10−3vs. 1.62±0.25 x 10−3 mm2/s, P < 0.001).


The addition of LDE225 to gemcitabine and nab-paclitaxel was well tolerated and showed promising anti-tumor activity, regardless of whether or not patients had received prior chemotherapy for metastatic pancreatic cancer.

Clinical trial identification

EudraCT number 2013-002370-51 NCT02358161

Legal entity responsible for the study

J.W. Wilmink Academic Medical Center Amsterdam - University of Amsterdam (AMC-UvA).


Academic Medical Center - University of Amsterdam (AMC-UvA) Novartis Pharma BV Cellgene BV.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.